NASDAQ:NVCR - Novocure Stock Price, Forecast & News

Novocure trades on the NASDAQ under the ticker symbol "NVCR."

Novocure Ltd (NASDAQ:NVCR) released its quarterly earnings results on Thursday, October, 31st. The medical equipment provider reported $0.02 EPS for the quarter, beating the Zacks' consensus estimate of ($0.05) by $0.07. The medical equipment provider had revenue of $92.06 million for the quarter, compared to analyst estimates of $87.12 million. Novocure had a negative net margin of 8.43% and a negative return on equity of 18.45%. The company's revenue for the quarter was up 42.2% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.13) earnings per share. View Novocure's Earnings History.

Novocure is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Novocure.

Novocure updated its FY 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $351.3-351.3 million, compared to the consensus revenue estimate of $347.69 million.

6 analysts have issued twelve-month target prices for Novocure's shares. Their forecasts range from $50.00 to $97.00. On average, they expect Novocure's share price to reach $80.33 in the next year. This suggests a possible upside of 1.1% from the stock's current price. View Analyst Price Targets for Novocure.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novocure in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Novocure.

Media headlines about NVCR stock have trended somewhat positive this week, InfoTrie reports. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Novocure earned a news impact score of 2.0 on InfoTrie's scale. They also gave headlines about the medical equipment provider a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for Novocure.

Novocure saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 4,110,000 shares, an increase of 5.4% from the January 15th total of 3,900,000 shares. Based on an average daily trading volume, of 906,500 shares, the short-interest ratio is presently 4.5 days. Approximately 5.2% of the shares of the company are sold short. View Novocure's Current Options Chain.

Some companies that are related to Novocure include FRESENIUS SE &/S (FSNUY), DexCom (DXCM), ResMed (RMD), Teleflex (TFX), Insulet (PODD), ABIOMED (ABMD), Hill-Rom (HRC), Penumbra (PEN), Haemonetics (HAE), Globus Medical (GMED), Integra Lifesciences (IART), Tandem Diabetes Care (TNDM), ICU Medical (ICUI), Nevro (NVRO) and NuVasive (NUVA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Novocure investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners, L.P (CLMT), Two Harbors Investment (TWO), Blackrock Capital Investment (BKCC), Viper Energy Partners (VNOM), Summit Midstream Partners (SMLP), Washington Prime Group (WPG), NVIDIA (NVDA) and Roper Technologies (ROP).

Novocure's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (12.31%), Baillie Gifford & Co. (8.09%), Capital World Investors (5.09%), Renaissance Technologies LLC (2.27%), State Street Corp (1.69%) and Capital International Investors (1.40%). Company insiders that own Novocure stock include Asaf Danziger, Charles G Phillips III, Eilon D Kirson, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen, William F Doyle and Yoram Palti. View Institutional Ownership Trends for Novocure.

NVCR stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Mitsubishi UFJ Trust & Banking Corp, Goldman Sachs Group Inc., Renaissance Technologies LLC, UBS Asset Management Americas Inc., Nicholas Investment Partners LP, Jacobs Levy Equity Management Inc. and Citigroup Inc.. Company insiders that have sold Novocure company stock in the last year include Asaf Danziger, Charles G Phillips III, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen and William F Doyle. View Insider Buying and Selling for Novocure.

NVCR stock was acquired by a variety of institutional investors in the last quarter, including Capital International Investors, Invus Financial Advisors LLC, FMR LLC, Fiera Capital Corp, Panagora Asset Management Inc., Geode Capital Management LLC, State Street Corp and Pictet Asset Management Ltd.. View Insider Buying and Selling for Novocure.

Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NVCR stock can currently be purchased for approximately $79.46.

Novocure has a market capitalization of $7.86 billion and generates $248.07 million in revenue each year. The medical equipment provider earns $-63,560,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis. View Additional Information About Novocure.

The official website for Novocure is http://www.novocure.com/.

Novocure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected]